Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors

International Journal of Biological Markers

Volumn 26, Issue 1, 2011, Pages 50-57

  Affy, Alaa M ^a   Tate, Stacey ^b   Durbin Johnson, Blythe ^c   Rocke, David M ^c   Konia, Thomas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Georgia Bureau of Investigation   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD44s; CD44v6; Lung cancer; Prognostic marker

Indexed keywords

CD44V6 ANTIGEN; HERMES ANTIGEN;

ARTICLE; BRONCHUS CARCINOID; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

ANTIGENS, CD44; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 79953656478     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2011.6291     Document Type: Article

References (42)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society, 2010.
2. Ogino S, Nishida N, Umemoto R, et al. Two-state conformations in the hyaluronan-binding domain regulate CD44 adhesiveness under fow condition. Structure 2010; 12: 649-56.
3. Haynes BF, Liao HX, Patton KL. The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. Cancer Cells 1991; 3: 347-50.
4. Tölg C, Hofmann M, Herrlich P, Ponta H. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acid Res 1993; 21: 1225-9.
5. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 2009; 119: 1518-30.
6. Yamada Y, Itano N, Narimatsu H, et al. CD44 variant exon 6 expressions in colon cancer assessed by quantitative analysis using real time reverse transcriptase-polymerase chain reaction. Oncol Rep 2003; 10: 1919-24.
7. Affy AM, Craig S, Paulino AF, Stern R. Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium. Ann Diagn Pathol 2005; 9: 312-8.
8. Affy AM, Ferguson AW, Davila RM, Werness BA. Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas. Appl Immunohistochem Mol Morphol 2001; 9: 309-14.
9. Günthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
10. Kaufmann M, Heider KH, Sinn HP, Von Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995; 345: 615-9.
11. Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, et al. Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance. World J Gastroenterol 2008; 14: 6376-81.
12. Ngan CY, Yamamoto H, Seshimo I, et al. A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. J Surg Oncol 2007; 95: 652-62.
13. Penno MB, August JT, Baylin SB, et al. Expression of CD44 in human lung tumors. Cancer Res 1994; 54: 1381-7.
14. Wimmel A, Kogan E, Ramaswamy A, Schuermann M. Variant expression of CD44 in preneoplastic lesions of the lung. Cancer 2001; 92: 1231-6.
15. McKee C, Penno MB, Cowman M, et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 1996; 98: 2403-13.
16. Johnson P, Ruffell B. CD44 and its role in infammation and infammatory diseases. Infamm Allergy Drug Targets 2009; 3: 208-20.
17. Van der Windt GJ, Florquin S, De Vos AF, et al. CD44 defciency is associated with increased bacterial clearance but enhanced lung infammation during Gram-negative pneumonia. Am J Pathol 2010; 177: 2483-94.
18. Sconocchia G, Campagnano L, Adorno D, et al. CD44 ligation on peripheral blood polymorphonuclear cells induces interleukin-6 production. Blood 2001; 97: 3621-27.
19. Svee K, White J, Vaillant P, et al. Acute lung injury fbroblast migration and invasion of a fbrin matrix is mediated by CD44. J Clin Invest 1996; 98: 1713-27.
20. DeGrendele HC, Kosfszer M, Estess P, Siegelman MH. CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation. J Immunol 1997; 159: 2546-53.
21. Clark RA, Alon R, Springer TA. CD44 and hyaluronan-dependent rolling interactions of lymphocytes on tonsillar stroma. J Cell Biol 1996; 134: 1075-87.
22. Puré E, Cuff CA. A crucial role for CD44 in infammation. Trends Mol Med 2001; 7: 213-21.
23. DeGrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an infammatory site. Science 1997; 278: 672-5.
24. Schmits R, Filmus J, Gerwin N, et al. CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood 1997, 90: 2217-33.
25. Teder P, Vandivier RW, Jiang D, et al. Resolution of lung infammation by CD44. Science 2002; 296: 155-8.
26. Sahu S, Lynn WS. Hyaluronic acid in the pulmonary secretions of patients with alveolar proteinosis. Infammation 1978; 3: 149-58.
27. Hällgren R, Samuelsson T, Laurent TC, Modig J. Accumulation of hyaluronan (hyaluronic acid) in the lung in adult respiratory distress syndrome. Am Rev Respir Dis 1989; 139: 682-7.
28. Wimmel A, Schilli M, Kaiser U, et al. Preferential histiotypic expression of CD44-isoforms in human lung cancer. Lung Cancer 1997; 16: 151-72.
29. Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H. Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of nonsmall cell lung carcinoma with intrapulmonary metastases. Cancer 1999; 86: 1174-81.
30. Kondo K, Miyoshi T, Hino N, et al. High frequency expressions of CD44 standard and variant forms in non-small cell lung cancers, but not in small cell lung cancers. J Surg Oncol 1998; 69: 128-36.
31. Ariza A, Mate JL, Isamat M, et al. Standard and variant CD44 isoforms are commonly expressed in lung cancer of the non-small cell type but not of the small cell type. J Pathol 1995; 177: 363-8.
32. Munchar MJ, Sharifah NA, Jamal R, Looi LM. CD44s expression correlated with the International Neuroblastoma Pathology Classifcation (Shimada system) for neuroblastic tumours. Pathology 2003; 35: 125-9.
33. Valentiner U, Valentiner FU, Schumacher U. Expression of CD44 is associated with a metastatic pattern of human neuroblastoma cells in a SCID mouse xenograft model. Tumour Biol 2008; 29: 152-60.
34. Bourguignon LY. Hyaluronan-mediated CD44 activation of Rho-GTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 2008; 18: 251-9.
35. Bourguignon L, Zhu H, Shao L, Chen Y. Ankyrin-Tiam1 interaction promotes Rac1 signaling and metastatic breast tumor cell invasion and migration. J Cell Biol 2000; 150: 177-91.
36. Tran TA, Kallakury BV, Sheehan CE, Ross JS. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol 1997; 28: 809-14.
37. Miyoshi T, Kondo K, Hino N, Uyama T, Monden Y. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer. Clin Cancer Res 1997; 3: 1289-97.
38. Ramasami S, Kerr KM, Chapman AD, King G, Cockburn JS, Jeffrey RR. Expression of CD44v6 but not E-cadherin or beta-catenin infuences prognosis in primary pulmonary adenocarcinoma. J Pathol 2000; 192: 427-32.
39. Hirata T, Fukuse T, Naiki H, Hitomi S, Wada H. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res 1998; 58: 1108-10.
40. Givehchian M, Woerner SM, Lacroix J, et al. Expression of CD44 splice variants in normal respiratory epithelium and bronchial carcinomas: no evidence for altered CD44 splicing in metastasis. Oncogene 1996; 12: 1137-44.
41. Suzuki H, Yamashiro K. Reduced expression of CD44 v3 and v6 is related to invasion in lung adenocarcinoma. Lung Cancer 2002; 38: 137-41.
42. Nguyen VN, Mirejovský T, Melinová L, Mandys V. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic signifcance. Neoplasma 2000; 47: 400-8.